Skip to main content

New concepts affecting the use of antiarrhythmic agents

Summary

Three underappreciated concepts having an important impact on the use of antiarrhythmic agents having Class I activity are discussed. These are stereochemical influences on antiarrhythmic action, the modulated receptor theory, and pharmacogenetics. The stereoisomers of some antiarrhythmic agents behave differently in terms of their potency, disposition, and antiarrhythmic action. For example, the enantiomers of both tocainide and mexiletine are cleared at different rates, and those of disopyramide have opposite effects on repolarization. The modulated receptor theory suggests that the affinity of antiarrhythmic drugs to bind to a specific receptor on or near the sodium channel depends on whether the sodium channel is open, resting, or inactivated. Study of the interaction between the state of the sodium channel and the differing actions of the antiarrhythmic agents have provided evidence for synergistic drug combinations. Pharmacogenetics relates to the differences observed in drug metabolism among individuals, which can result in variations of two- to fourfold in clearance and plasma concentration in some cases. There is still much to learn about Class I antiarrhythmic agents. These concepts should lead to a better understanding of their actions and increase their utility.

This is a preview of subscription content, access via your institution.

References

  1. Thomas AH, Murdoch G, Pottage A, et al. The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias. Br J Clin Pharmacol 1986;91:149–154.

    Google Scholar 

  2. Grech-Belanger O, Turgeon J, Gilbert M. Stereoselective disposition of mexiletine in man. Br J Clin Pharmacol 1986;21:481–487.

    Google Scholar 

  3. Giacomini KM, Cox BM, Blaschke TF. Comparative anticholinergic potencies of R- and S-disopyramide in longitudinal muscle strips from guinea pig ileum. Life Sci 1980; 27:1191–1197.

    Google Scholar 

  4. U'Prichard ACG, Allen JF, Harron DWG. Effects of tocainide enantiomers on experimental arrhythmias produced by programmed electrical stimulation. J Cardiovasc Pharmacol 1988;11:235–241.

    Google Scholar 

  5. Sheldon RS, Cannon NJ, Nies AS, Duff HJ. Stereospecific interaction of tocainide with the cardiac sodium channel. Mol Pharmacol 1988;33:327–331.

    Google Scholar 

  6. Eichelbaum M, Mikus G, Vogelgesang B. Pharmacokinetics of (+)-, (-)-, and (+)-verapmil after intravenous administration. Br J Clin Pharmacol 1984;17:453–458.

    Google Scholar 

  7. Hondeghem L, Katzung BG. Test of a model of antiarrhythmic drug action: Effects of quinidine and lidocaine on myocardial conduction. Circulation 1980;61:1217–1224.

    Google Scholar 

  8. Varro A, Elharrar V, Surawicz B. Frequency-dependent effects of several Class I antiarrhythmic drugs on Vmax of action potential upstroke in canine cardiac Purkinje fibers, J Cardiovasc Pharmacol 1985;7:482–492.

    Google Scholar 

  9. Moyer JW, Hondeghem LM. Effects of the combination of quinidine and lidocaine on the upstroke velocity of the cardiac action potential. Proc West Pharmacol Soc 1980;23: 159–161.

    Google Scholar 

  10. Duff HJ, Roden DM, Primm RK, et al. Mexiletine in the treatment of resistant ventricular arrhythmias: Enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation 1983;67:1124–1128.

    Google Scholar 

  11. Whitford EG, McGovern B, Schoenfeld MH, et al. Longterm efficacy of mexiletine alone and in combination with Class IA antiarrhythmic drugs for refractory ventricular arrhythmias. Am Heart J 1988;115:360–366.

    Google Scholar 

  12. Guengerich FP, Umbenhauer DR, Churchill PF, et al. Polymorphism of human cytochrome P-450. Xenobiotica 1987; 17:311–316.

    Google Scholar 

  13. Woosley RL, Roden DM, Dai G, et al. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther 1986;39:282–287.

    Google Scholar 

  14. Siddoway LA, Thompson KA, Mcallister CB, et al. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences, Circulation 1987;75:785–791.

    Google Scholar 

  15. Beckman J. The poor metabolism phenotype for polymorphic spartine/debrisoquin oxidation: A predisposing factor for flecainide toxicity, Br J Pharmacol 1989;28:555–566.

    Google Scholar 

  16. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986;30:287.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Woosley, R.L. New concepts affecting the use of antiarrhythmic agents. Cardiovascular Drugs and Therapy 4, 541–544 (1990). https://doi.org/10.1007/BF00357026

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00357026

Key Words

  • antiarrhythmic agents
  • modulated receptor theory
  • enantiomers
  • pharmacogenetics